CN115811987A - 抗神经酰胺抗体 - Google Patents

抗神经酰胺抗体 Download PDF

Info

Publication number
CN115811987A
CN115811987A CN202180034154.0A CN202180034154A CN115811987A CN 115811987 A CN115811987 A CN 115811987A CN 202180034154 A CN202180034154 A CN 202180034154A CN 115811987 A CN115811987 A CN 115811987A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180034154.0A
Other languages
English (en)
Chinese (zh)
Inventor
R·科莱斯尼克
A·廷克伦贝格
J·K-M·王
Y·吴
Y·王
R·利维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerlatec Holdings Ltd
Memorial Sloan Kettering Cancer Center
Original Assignee
Cerlatec Holdings Ltd
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerlatec Holdings Ltd, Memorial Sloan Kettering Cancer Center filed Critical Cerlatec Holdings Ltd
Publication of CN115811987A publication Critical patent/CN115811987A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180034154.0A 2020-03-18 2021-03-18 抗神经酰胺抗体 Pending CN115811987A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062991232P 2020-03-18 2020-03-18
US62/991,232 2020-03-18
PCT/US2021/022914 WO2021188770A1 (en) 2020-03-18 2021-03-18 Anti-ceramide antibodies

Publications (1)

Publication Number Publication Date
CN115811987A true CN115811987A (zh) 2023-03-17

Family

ID=77771401

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180034154.0A Pending CN115811987A (zh) 2020-03-18 2021-03-18 抗神经酰胺抗体

Country Status (11)

Country Link
US (1) US12655229B2 (cg-RX-API-DMAC10.html)
EP (1) EP4121110B1 (cg-RX-API-DMAC10.html)
JP (2) JP7809067B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230031814A (cg-RX-API-DMAC10.html)
CN (1) CN115811987A (cg-RX-API-DMAC10.html)
AU (1) AU2021236669A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022018682A2 (cg-RX-API-DMAC10.html)
CA (1) CA3172201A1 (cg-RX-API-DMAC10.html)
IL (1) IL296550A (cg-RX-API-DMAC10.html)
MX (1) MX2022011591A (cg-RX-API-DMAC10.html)
WO (1) WO2021188770A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201700787XA (en) 2014-08-07 2017-02-27 Sloan Kettering Inst Cancer Anti-ceramide antibodies
BR112023018758A2 (pt) * 2021-03-16 2023-11-28 Univ Michigan State Intensificação de cicatrização de ferida com anticorpos anticeramida

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278907A1 (en) * 2008-04-22 2010-11-04 Medical College Of Georgia Research Institute, Inc Immunogenic Compositions Containing Ceramide and Methods of Use Thereof
CN102264391A (zh) * 2008-08-20 2011-11-30 森托科尔奥索生物科技公司 工程化抗il-13抗体、组合物、方法和用途
CN107074949A (zh) * 2014-08-07 2017-08-18 索隆-基特林癌症研究协会 抗神经酰胺抗体
CN110337448A (zh) * 2016-12-23 2019-10-15 瑞美德生物医药科技有限公司 使用与程序性死亡配体1(pd-l1)结合的抗体的免疫疗法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
CA2398466A1 (en) 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
JP2008528010A (ja) 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ 重鎖抗体の可変ドメイン配列を作出する方法
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
US9833949B2 (en) 2011-08-29 2017-12-05 Impossible Objects, Inc. Apparatus for fabricating three-dimensional printed composites
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
CA3081058C (en) * 2015-01-16 2024-02-20 Academia Sinica Linker units and their uses in configuring pharmaceutical molecules
PL3618842T3 (pl) * 2017-05-01 2024-02-19 Juno Therapeutics, Inc. Kombinacja terapii komórkowej i związku immunomodulującego
WO2019237035A1 (en) * 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
BR112023018758A2 (pt) * 2021-03-16 2023-11-28 Univ Michigan State Intensificação de cicatrização de ferida com anticorpos anticeramida

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278907A1 (en) * 2008-04-22 2010-11-04 Medical College Of Georgia Research Institute, Inc Immunogenic Compositions Containing Ceramide and Methods of Use Thereof
CN102264391A (zh) * 2008-08-20 2011-11-30 森托科尔奥索生物科技公司 工程化抗il-13抗体、组合物、方法和用途
CN107074949A (zh) * 2014-08-07 2017-08-18 索隆-基特林癌症研究协会 抗神经酰胺抗体
CN110337448A (zh) * 2016-12-23 2019-10-15 瑞美德生物医药科技有限公司 使用与程序性死亡配体1(pd-l1)结合的抗体的免疫疗法

Also Published As

Publication number Publication date
CA3172201A1 (en) 2021-09-23
IL296550A (en) 2022-11-01
JP2026104852A (ja) 2026-06-25
JP2023534779A (ja) 2023-08-14
MX2022011591A (es) 2023-03-06
JP7809067B2 (ja) 2026-01-30
US12655229B2 (en) 2026-06-16
KR20230031814A (ko) 2023-03-07
US20230167197A1 (en) 2023-06-01
BR112022018682A2 (pt) 2023-02-14
AU2021236669A1 (en) 2022-11-10
EP4121110A4 (en) 2024-06-12
WO2021188770A1 (en) 2021-09-23
EP4121110A1 (en) 2023-01-25
EP4121110B1 (en) 2026-05-27

Similar Documents

Publication Publication Date Title
CN112566935B (zh) 抗ox40抗体和使用方法
JP7425604B2 (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
JP6734436B2 (ja) 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用
AU2016239858B2 (en) Antibodies to canine interleukin-4 receptor alpha
JP2020018298A (ja) Ｃｌｄｎ１８．２及びｃｄ３に対する抗体コンストラクト
AU2019254934B2 (en) Monoclonal antibody of nerve growth factor and encoding gene and use thereof
IL293138A (en) Antibodies to cd3 and bcma and bispecific binding proteins produced from them
JP2018524997A (ja) Ｅｇｆｒｖｉｉｉ及びｃｄ３に結合する二重特異性抗体構築物
TW202126691A (zh) Ｃｄ３９的高親和力抗體及其用途
KR102678252B1 (ko) 재조합 이중특이적 항체
CN116133684B (zh) 抗人nr1抗体衍生物
EP4292611A1 (en) Anti-cd112r antibody and use thereof
CN110003338A (zh) 抗ox40抗体及其应用
CN116262135B (zh) 抗cd27抗体组合物及其用途
JP2019514871A (ja) 骨髄性白血病の治療方法で使用するための、ｃｄ３３とｃｄ３に結合する二重特異性構築物の投与の方法
TWI836069B (zh) 抗-sema3a抗體及其用於治療眼或眼部疾病之用途
WO2019076277A1 (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
CN116262789A (zh) 嵌合的抗cd27抗体
CN116262790A (zh) 嵌合的抗cd27抗体组合物及其应用
JP7809067B2 (ja) 抗セラミド抗体
CN116574189A (zh) 针对人il-36r和/或人il-1r3的多种抗体及其用途
CN114269788A (zh) 一种能够与人4-1bb结合的分子及其应用
JP7510209B2 (ja) ヘルパーＴ細胞ＴＧＦ－βシグナルを特異的に中和する二重特異性抗体、その薬物組成物およびその使用
CN114641500B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
CN114729051A (zh) 使用抗ox40抗体与放射组合治疗癌症的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination